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anglais
During advanced vasodilatory shock, arginine vasopressin (AVP) is increasingly
used to restore blood pressure and thus to reduce catecholamine requirements.
The AVP-related rise in mean arterial pressure is due to systemic vasoconstriction,
which, depending on the infusion rate, may also reduce coronary blood flow
despite an increased coronary perfusion pressure. In a murine model of
myocardial ischaemia, Indrambarya and colleagues now report that a 3-day
infusion of AVP decreased the left ventricular ejection fraction, ultimately
resulting in increased mortality, and thus compared unfavourably with a standard
treatment using dobutamine. The AVP-related impairment myocardial dysfunction
did not result from the increased left ventricular afterload but from a direct effect
on cardiac contractility. Consequently, the authors conclude that the use of AVP
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